Merck & Company Inc (MRK)vsDentsply Sirona Inc (XRAY)
MRK
Merck & Company Inc
$149.57
+1.79%
HEALTHCARE · Cap: $355.10B
XRAY
Dentsply Sirona Inc
$9.44
-1.05%
HEALTHCARE · Cap: $2.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1727% more annual revenue ($66.57B vs $3.64B). MRK leads profitability with a 4.8% profit margin vs -15.0%. XRAY appears more attractively valued with a PEG of 0.71. XRAY earns a higher WallStSmart Score of 53/100 (C-).
MRK
Hold36
out of 100
Grade: F
XRAY
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-77.2%
Fair Value
$83.04
Current Price
$149.57
$66.53 premium
Margin of Safety
+69.5%
Fair Value
$45.01
Current Price
$9.44
$35.57 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Growing faster than its price suggests
Areas to Watch
Trading at 8.8x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Elevated debt levels
ROE of -37.7% — below average capital efficiency
Revenue declined 4.1%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : XRAY
The strongest argument for XRAY centers on Price/Book, PEG Ratio. PEG of 0.71 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : XRAY
The primary concerns for XRAY are Debt/Equity, Return on Equity, Revenue Growth. Debt-to-equity of 1.71 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while XRAY is a turnaround play — different risk/reward profiles.
XRAY carries more volatility with a beta of 0.85 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
XRAY scores higher overall (53/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Dentsply Sirona Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Dentsply Sirona is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?